Last update Sept. 17, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Κυπροεπταδίνη υδροχλωρική is Cyproheptadine Hydrochloride in Greek.Is written in other languages:
Κυπροεπταδίνη υδροχλωρική belongs to this group or family:
|Oral Bioavail.||Alta - Hig||%|
|Tmax||oral: 4 / sublingual: 9||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cyproheptadine, a derivative of piperidine, is a first-generation antihistamine with a moderate sedative effect. It has antimuscarinic, serotonin antagonist and calcium channel blocker actions. It is used for the symptomatic relief of allergic conditions, such as hives and angioedema, rhinitis and conjunctivitis. It is also used in the control of migraine and for appetite stimulation. Oral administration three to four times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high percentage of protein binding make it highly unlikely that significant quantities will pass into breast milk.
Cyproheptadine lowers prolactin levels and has been used to treat galactorrhea (Wortsman 1979). The stimulation of the infant's suckling is usually sufficient to ensure the production of breast milk. (Messinis 1985)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Somnolence and adequate feeding of the infant should be monitored.
Bed-sharing with the baby is not recommended if drugs are used due to increased risk of suffocation or sudden infant death. (ABM 2020 y 2008, UNICEF 2018, 2017, 2014 y 2013, Landa 2012, UNICEF 2006)